{
    "nctId": "NCT02726009",
    "officialTitle": "An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon\u00ae in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer",
    "inclusionCriteria": "* Has given written informed consent before any study-related activity is performed\n* Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon\u00ae is intended to be used for treatment\n* Age greater than or equal to 18 years and less than 80 years\n* Advanced hormone-dependent prostate cancer without any other clinically significant disorder\n* Easten Cooperative Oncology Group score \u2264 2\n* PSA \u2265 2 ng/mL at screening\n* Life expectancy of at least 12 months as per the investigator's judgement\n* Must be MALE\n* Must have minimum age of 18 Years\n* Must have maximum age of 79 Years",
    "exclusionCriteria": "* Previous or concurrent hormonal management of prostate cancer\n* Contraindication for prescription of Firmagon\u00ae\n* Concurrent treatment with a 5-\u03b1-reductase inhibitor\n* Considered as a candidate for curative therapy\n* History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema\n* QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications\n* Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin\n* Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment)\n* Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer\n* Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections"
}